After its drug Palifosfamide failed to show efficacy in a phase 3 sarcoma trial, shares of Ziopharm Oncology (NASDAQ:ZIOP) fell through the floor, dropping by more than 66%. Do shareholders have any hope of a recovery? In this video, Motley Fool health-care analyst David Williamson takes us through what the cash situation looks like at Ziopharm, where the company will be shifting its focus next, and what, if any, hope remains.
- Mar 26, 2013 at 7:37PM
- Health Care